Integer Holdings Corp (ITGR) · Oct 21, 2026 · Acquisition
Shareholder approval — 99.95% of shares voted favored the merger
Integer’s acquisition vote passes overwhelmingly, clearing the shareholder hurdle while regulatory approvals remain before the deal can close.
The vote advances a planned take-private, not Integer’s operating strategy. Integer is a medical-device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. The board’s April strategic review and August merger agreement already established the sale process, making this shareholder vote a scheduled milestone rather than a new strategic surprise.
Shareholders cleared the required approval hurdle by a wide margin. Approximately 99.95% of shares voted on the merger proposal supported it, representing 76.66% of total shares outstanding as of the record date. 〔0〕 (Special Meeting results) The separate advisory vote on transaction-related executive compensation also passed. 〔1〕 (Special Meeting results)
The transaction is closer, but not yet certain. The company still expects closing by the end of 2026, subject to customary conditions and required regulatory approvals. 〔2〕 (Closing conditions) Because shareholder approval was already expected, the filing mainly removes execution risk around the vote; it does not add new information about Integer’s underlying business or change the remaining regulatory path.
Bottom line: The sale moves through its expected shareholder checkpoint with overwhelming support. It materially advances completion logistics but leaves regulatory approval as the main unresolved step, so the business story itself is largely unchanged until closing.
Regulatory approvals and deal closing by end-2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!